177Lu-J591; 117Lu-J591; 177Lu−J591; lutetium Lu 177 monoclonal antibody J591; TX591; TLX591; 177Lu-DOTA-Rosopatamab; 177Lu-DOTA-TLX591-CHO; 177Lu-DOTA-rosopatamb; 177Lu-TLX591; 177Lu-DOTA-TLX591 药品类别 创新药; 生物; 抗体; potential first-in-class; 放射性药物; 偶联药物...
(PC) as it is highly expressed by malignant prostate cells.1,2 177LuDOTA-HuJ591-CHO (hereafter referred to as 177Lu-TLX591) is a radioimmunoconjugate comprised of the humanized IgG1 mAb rosopatamab, linked to the low energy beta-emitting radioisotope lutetium177 (Lu-177) via the ...
Étude de phase III évaluant le traitement de référence seul ou en combinaison avec le 177Lu-TLX591 dans le CPRCm post-traitement anti-androgénique Médecine Nucléaire Volume 49, Issue 1, February 2025, Page 21 Purchase options CorporateFor R&D professionals working in corporate organizations...
Lu-TLX591 monoclonal antibody is a potential agent of significance; however, to date, reports on its toxicity and efficacy have been limited to small clinical trials in heavily pretreated patients. This retrospective study describes the real-world toxicity and efficacy profile of Lu-TLX591.#...
Patients will be enrolled in 1) a safety and dosimetry lead-in (N=30) and 2) a randomized treatment expansion (N=400) in a 2:1 ratio to receive best protocol-defined standard of care (SoC) with or without 2 intravenous injections of 2.8 GBq TLX591, given 14 days apart. SoC may ...
Lu-TLX591 monoclonal antibody is a potential agent of significance; however, to date, reports on its toxicity and efficacy have been limited to small clinical trials in heavily pretreated patients. This retrospective study describes the real-world toxicity and efficacy profile of Lu-TLX591.#...
(PC) as it is highly expressed by malignant prostate cells.1,2 177Lu-DOTA-HuJ591-CHO (TLX591) is a radioimmunoconjugate comprised of the humanized IgG1 mAb rosopatamab, linked to the low energy beta-emitting radioisotope lutetium-177 (177Lu) via the bifunctional chelating agent DOTA-NHS ...
(PC) as it is highly expressed by malignant prostate cells.1,2 177Lu-DOTA-HuJ591-CHO (TLX591) is a radioimmunoconjugate comprised of the humanized IgG1 mAb rosopatamab, linked to the low energy beta-emitting radioisotope lutetium-177 (177Lu) via the bifunctional chelating agent DOTA-NHS ...
Cohort 1: 5 patients received a single (27 mCi) intravenous infusion of177Lu-TLX591. SPECT images and pharmacokinetic blood samples will be acquired at several time points until Day 13 after dosing. Dosimetry analysis and qualitative comparison of biodistribution of tracer level of177Lu-TLX591, ...
177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT)doi:10.1016/S2666-1683(22)02370-9K. O'ByrneD. MeyrickN. PatelF. FantinoC. HaywardElsevier B.V.European Urology Open Science